SAN ANTONIO (EGMN) - Sorafenib in combination with either paclitaxel or capecitabine for treatment of locally advanced or metastatic breast cancer demonstrated both impressive efficacy and problematic toxicity, compared with chemotherapy alone, in two phase IIB clinical trials presented at the San Antonio Breast Cancer Symposium.The concerning toxicity took the form of hand-foot syndrome (HFS). The incidence of grade 3 HFS in sorafenib-treated patients was 30% in one double-blind randomized trial...